|Bid||26.22 x 68800|
|Ask||27.00 x 1500|
|Day's range||26.14 - 26.65|
|52-week range||21.50 - 27.73|
|PE ratio (TTM)||27.10|
|Earnings date||26 Jul 2018 - 2 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||25.56|
May 10 (Reuters) - Boya Bio-Pharmaceutical Group Co Ltd : * SAYS IT SIGNS AGREEMENT WITH GRIFOLS S.A. TO SET UP BLOOD PLASMA STATIONS WITH INITIAL INVESTMENT AT ABOUT 50 MILLION EUROS ($59.30 million) ...
We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.
Grifols shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.
A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Barclays remains bullish on the European telecoms, seeing positive revenue and EBITDA growth in 2018 across the ...
A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Royal Mail: Credit Suisse downgrades to "underperform" expecting worse letter revenue and a costly labour ...
European shares dipped on Friday as another North Korean missile launch softened appetite for riskier banks and miners but still scored their strongest week since July as attractive valuations tempted ...